Cancer Prevention and Control CIRB Meeting Agenda
May 26, 2022

I. Amendment Prior to Activation

MDA20-01-01, A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP) (Protocol Version Date 04/11/22)

II. Continuing Review

A211901, Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions (Protocol Version Date 10/15/21)

III. Continuing Review

EAQ171CD, Implementing a Virtual Tobacco Treatment in Community Oncology Practices: “Smoke Free Support Study 2.0” (Protocol Version Date 07/01/21)

IV. Continuing Review

S1501, Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III (Protocol Version Date 07/07/21)

V. Continuing Review

UAZ20-01-01, Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy (Protocol Version Date 01/24/22)

VI. Continuing Review

URCC-18007, Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue (Protocol Version Date 06/17/20)
VII. New Study Review

UWI20-04-01, A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer (Protocol Version Date 05/17/22)

VIII. New Study - Initial Review

NRG-CC010, A Phase III Trial of the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer (Protocol Version Date 05/05/22)

IX. Amendment Review

S1614, A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors (Protocol Version Date 05/02/22)